Accelrys Announces Strategic Distribution Agreement

Accelrys to Embed Oracle(R) Technology

Into Discovery Studio Project Knowledge Manager Plus

Sep 23, 2003, 01:00 ET from Accelrys, Inc.

    SAN DIEGO, Sept. 23 /PRNewswire-FirstCall/ -- Accelrys, Inc., a wholly
 owned subsidiary of Pharmacopeia, Inc. (Nasdaq:   PCOP) and active member of the
 Oracle PartnerNetwork, today announced a strategic agreement in which Accelrys
 will embed Oracle(R) technology into Accelrys' Discovery Studio(R) family of
 products.  Under the terms of the agreement, Accelrys will embed Oracle(R)
 Database and associated software in Discovery Studio Project Knowledge Manager
 Plus (DS ProjectKM Plus), the core component of Accelrys' Discovery Studio's
 knowledge-centric system.  Accelrys will resell the Oracle Database, and will
 facilitate the seamless integration of Oracle for all Discovery Studio related
 data management needs -- for both individual workstations and at the
 enterprise level.
     "Accelrys is a leading provider of life science discovery software and we
 are pleased that they have chosen to embed Oracle technology into Discovery
 Studio," said Robert Shimp, vice president, Platform Marketing at Oracle.
 "Oracle Database is already the database of choice for life sciences
 infrastructure. This relationship will extend the availability of
 next-generation technology to a new class of researchers."
     "This agreement emphasizes Accelrys' commitment to ensuring that our
 customers have a cost effective way to apply the technology best suited to
 their needs," said Mark Emkjer, president of Accelrys.  "The combination of
 Accelrys and Oracle in DS ProjectKM Plus will allow research scientists in the
 chemical and pharmaceutical industries to benefit from Accelrys' expertise as
 one of the leading developers of scientific software, as well as from the
 reliability and security features of the Oracle Database, the Life Sciences
 industry standard for data storage."
     DS ProjectKM Plus facilitates the exchange of information between
 researchers, breaking down the barriers between scientific disciplines that
 ordinarily restrict collaboration.  Data and results from across a research
 organization, together with their often-complex inter-relationships, are
 captured in a central database.  Provided a user has the proper security
 permissions, he or she can quickly find relevant data that otherwise might
 previously have been inaccessible.  Such secure exchange will improve the R&D
 process behind the design and development of novel drugs, chemicals, and
     DS ProjectKM Plus will be available to commercial customers along with
 Discovery Studio Modeling v1.1, available October 2003.
     About Discovery Studio
     Discovery Studio is a powerful research environment for the life sciences
 that delivers a comprehensive suite of informatics, modeling, and simulation
 solutions. This environment is composed of a wide breadth of tools,
 client-server applications, and databases for handling the specific research
 problems encountered by scientists working in the discovery process. The
 Discovery Studio design enables collaboration across scientific disciplines
 through a centralized project and knowledge management system, connecting the
 research conducted by biologists and chemists. In addition, Discovery Studio
 is an open platform built on industry-standard components so that it can
 leverage existing IT infrastructure and the integration of third-party
 applications, public domain, and other in-house developed applications. More
 information on Discovery Studio can be found at
     About the Oracle PartnerNetwork
     The Oracle PartnerNetwork is a global business network of more than
 12,000 companies who deliver innovative enterprise software solutions based on
 Oracle software. Through access to Oracle's premier products, education,
 technical services, marketing and sales support, the Oracle PartnerNetwork
 provides partners with the resources they need to be successful in today's
 Internet economy. Oracle partners are able to offer customers leading-edge
 solutions backed by Oracle's position as the world's largest enterprise
 software company.
     About Accelrys
     Accelrys is a leading provider of software for computation, simulation,
 and the management and mining of scientific data used by biologists, chemists,
 and materials scientists for product design, drug discovery, and development.
 Accelrys' platform technology and consulting services enable enterprise-wide
 solutions tailored to today's leading research organizations.  The company's
 two main centers of excellence are in San Diego, and Cambridge, UK.  These
 centers combine research and product development with facilities to support
 significant collaborative projects.  Accelrys is a subsidiary of Pharmacopeia,
 Inc. (Nasdaq:   PCOP).  More information on Accelrys can be found at
     Oracle is a registered trademark of Oracle Corporation and/or its
     When used anywhere in this document, the words expects, believes,
 anticipates, estimates, and similar expressions are intended to identify
 forward-looking statements. Forward-looking statements herein may include
 statements addressing future financial and operating results of Pharmacopeia.
 Pharmacopeia has based these forward-looking statements on its current
 expectations about future events. Such statements are subject to risks and
 uncertainties including, but not limited to, the successful implementation of
 Pharmacopeia's strategic plans, the acceptance of new products, the
 obsolescence of existing products, the resolution of existing and potential
 future patent issues, additional competition, changes in economic conditions,
 and other risks described in documents Pharmacopeia has filed with the
 Securities and Exchange Commission, including its most recent report on Form
 10-K and subsequent reports on Form 10-Q. All forward-looking statements in
 this document are qualified entirely by the cautionary statements included in
 this document and such filings. These risks and uncertainties could cause
 actual results to differ materially from results expressed or implied by
 forward-looking statements contained in this document. These forward-looking
 statements speak only as of the date of this document. Pharmacopeia disclaims
 any undertaking to publicly update or revise any forward-looking statements
 contained herein to reflect any change in its expectations with regard thereto
 or any change in events, conditions or circumstances on which any such
 statement is based.
      Public Relations Contacts:
      Jim Rivas
      Accelrys, Inc.
      (858) 799-5393

SOURCE Accelrys, Inc.